• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

N(4)-(取代苯基)-N(4)-烷基/去烷基-9H-嘧啶并[4,5-b]吲哚-2,4-二胺的合成及鉴定对多药耐药细胞有效的新型微管破坏化合物。

Synthesis of N(4)-(substituted phenyl)-N(4)-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells.

机构信息

Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA.

出版信息

Bioorg Med Chem. 2013 Feb 15;21(4):891-902. doi: 10.1016/j.bmc.2012.12.010. Epub 2012 Dec 20.

DOI:10.1016/j.bmc.2012.12.010
PMID:23332369
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3572549/
Abstract

A series of fourteen N(4)-(substituted phenyl)-N(4)-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines was synthesized as potential microtubule targeting agents. The synthesis involved a Fisher indole cyclization of 2-amino-6-hydrazinylpyrimidin-4(3H)-one with cyclohexanone, followed by oxidation, chlorination and displacement with appropriate anilines. Compounds 6, 14 and 15 had low nanomolar potency against MDA-MB-435 tumor cells and depolymerized microtubules. Compound 6 additionally had nanomolar GI(50) values against 57 of the NCI 60-tumor panel cell lines. Mechanistic studies showed that 6 inhibited tubulin polymerization and [(3)H]colchicine binding to tubulin. The most potent compounds were all effective in cells expressing P-glycoprotein or the βIII isotype of tubulin, which have been associated with clinical drug resistance. Modeling studies provided the potential interactions of 6, 14 and 15 within the colchicine site.

摘要

合成了一系列 14 种 N(4)-(取代苯基)-N(4)-烷基/去烷基-9H-嘧啶并[4,5-b]吲哚-2,4-二胺,作为潜在的微管靶向剂。该合成涉及 2-氨基-6-肼基嘧啶-4(3H)-酮与环己酮的 Fisher 吲哚环化反应,然后进行氧化、氯化和与适当苯胺的取代。化合物 6、14 和 15 对 MDA-MB-435 肿瘤细胞具有低纳摩尔效力,并使微管解聚。化合物 6 对 NCI 60 肿瘤面板细胞系中的 57 种具有纳摩尔 GI(50)值。机制研究表明,化合物 6 抑制微管蛋白聚合和 [(3)H]秋水仙碱与微管蛋白的结合。最有效的化合物在表达 P-糖蛋白或微管 βIII 同工型的细胞中均有效,这些同工型与临床药物耐药性有关。建模研究提供了化合物 6、14 和 15 在秋水仙碱结合位点的潜在相互作用。

相似文献

1
Synthesis of N(4)-(substituted phenyl)-N(4)-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells.N(4)-(取代苯基)-N(4)-烷基/去烷基-9H-嘧啶并[4,5-b]吲哚-2,4-二胺的合成及鉴定对多药耐药细胞有效的新型微管破坏化合物。
Bioorg Med Chem. 2013 Feb 15;21(4):891-902. doi: 10.1016/j.bmc.2012.12.010. Epub 2012 Dec 20.
2
Design, synthesis, and structure-activity relationships of pyrimido[4,5-b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells.作为对多药耐药细胞有效的微管解聚剂的嘧啶并[4,5-b]吲哚-4-胺的设计、合成及构效关系
Bioorg Med Chem Lett. 2017 Aug 1;27(15):3423-3430. doi: 10.1016/j.bmcl.2017.05.085. Epub 2017 May 27.
3
Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.水溶性微管靶向剂的合成与发现,该靶向剂与微管蛋白上的秋水仙素结合部位结合,并规避 Pgp 介导的耐药性。
J Med Chem. 2010 Nov 25;53(22):8116-28. doi: 10.1021/jm101010n. Epub 2010 Oct 25.
4
Janus Compounds, 5-Chloro-N⁴-methyl-N⁴-aryl-9H-pyrimido[4,5-b]indole-2,4-diamines, Cause Both Microtubule Depolymerizing and Stabilizing Effects.Janus化合物,5-氯-N⁴-甲基-N⁴-芳基-9H-嘧啶并[4,5-b]吲哚-2,4-二胺,兼具微管解聚和稳定作用。
Molecules. 2016 Dec 2;21(12):1661. doi: 10.3390/molecules21121661.
5
Synthesis and biological evaluation of indole-2-carbohydrazides and thiazolidinyl-indole-2-carboxamides as potent tubulin polymerization inhibitors.吲哚-2-甲酰肼和噻唑烷-吲哚-2-甲酰胺的合成及作为潜在的微管蛋白聚合抑制剂的生物评价。
Comput Biol Chem. 2019 Jun;80:512-523. doi: 10.1016/j.compbiolchem.2019.05.002. Epub 2019 May 11.
6
Simple monocyclic pyrimidine analogs as microtubule targeting agents binding to the colchicine site.简单的单环嘧啶类似物作为微管靶向剂,与秋水仙碱结合位点结合。
Bioorg Med Chem. 2023 Mar 15;82:117217. doi: 10.1016/j.bmc.2023.117217. Epub 2023 Feb 24.
7
Synthesis and biological evaluation of 2,4,5-substituted pyrimidines as a new class of tubulin polymerization inhibitors.合成及生物评价 2,4,5-取代嘧啶类化合物作为一类新型的微管蛋白聚合抑制剂。
J Med Chem. 2011 May 12;54(9):3200-5. doi: 10.1021/jm101388d. Epub 2011 Apr 11.
8
Novel water-soluble substituted pyrrolo[3,2-d]pyrimidines: design, synthesis, and biological evaluation as antitubulin antitumor agents.新型水溶性取代吡咯并[3,2-d]嘧啶类化合物的设计、合成及作为抗微管蛋白抗肿瘤剂的生物评价。
Pharm Res. 2012 Nov;29(11):3033-9. doi: 10.1007/s11095-012-0816-3. Epub 2012 Jul 20.
9
Design, Synthesis and Molecular Docking Studies of Novel Indole-Pyrimidine Hybrids as Tubulin Polymerization Inhibitors.新型吲哚 - 嘧啶杂化物作为微管蛋白聚合抑制剂的设计、合成及分子对接研究
Chem Biol Drug Des. 2015 Dec;86(6):1491-500. doi: 10.1111/cbdd.12616. Epub 2015 Aug 3.
10
Design, Synthesis, and Biological Evaluation of 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-]pyrimidines as Microtubule Targeting Agents.5,6,7,8-四氢苯并[4,5]噻吩并[2,3-d]嘧啶类化合物的设计、合成及作为微管靶向剂的生物评价。
Molecules. 2022 Jan 5;27(1):321. doi: 10.3390/molecules27010321.

引用本文的文献

1
Design, Synthesis, and Biological Evaluation of 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-]pyrimidines as Microtubule Targeting Agents.5,6,7,8-四氢苯并[4,5]噻吩并[2,3-d]嘧啶类化合物的设计、合成及作为微管靶向剂的生物评价。
Molecules. 2022 Jan 5;27(1):321. doi: 10.3390/molecules27010321.
2
Pyrido-Fused Deazapurine Bases: Synthesis and Glycosylation of 4-Substituted 9-Pyrido[2',3':4,5]- and Pyrido[4',3':4,5]pyrrolo[2,3-]pyrimidines.吡啶并稠合脱氮嘌呤碱基:4-取代的9-吡啶并[2',3':4,5]-和吡啶并[4',3':4,5]吡咯并[2,3-]嘧啶的合成与糖基化
ACS Omega. 2020 Oct 2;5(40):26278-26286. doi: 10.1021/acsomega.0c04302. eCollection 2020 Oct 13.
3
Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.秋水仙碱结合位点药物 DJ95 克服耐药性并显示抗肿瘤疗效。
Mol Pharmacol. 2019 Jul;96(1):73-89. doi: 10.1124/mol.118.114801. Epub 2019 May 1.
4
Design, synthesis, and structure-activity relationships of pyrimido[4,5-b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells.作为对多药耐药细胞有效的微管解聚剂的嘧啶并[4,5-b]吲哚-4-胺的设计、合成及构效关系
Bioorg Med Chem Lett. 2017 Aug 1;27(15):3423-3430. doi: 10.1016/j.bmcl.2017.05.085. Epub 2017 May 27.
5
Janus Compounds, 5-Chloro-N⁴-methyl-N⁴-aryl-9H-pyrimido[4,5-b]indole-2,4-diamines, Cause Both Microtubule Depolymerizing and Stabilizing Effects.Janus化合物,5-氯-N⁴-甲基-N⁴-芳基-9H-嘧啶并[4,5-b]吲哚-2,4-二胺,兼具微管解聚和稳定作用。
Molecules. 2016 Dec 2;21(12):1661. doi: 10.3390/molecules21121661.
6
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.7-苄基-N-(取代)-吡咯并[3,2-d]嘧啶-4-胺作为具有微管靶向作用的单一药物以及具有三重作用的血管激酶抑制作用的抗肿瘤药物的发现与临床前评估。
Bioorg Med Chem. 2017 Jan 15;25(2):545-556. doi: 10.1016/j.bmc.2016.11.026. Epub 2016 Nov 15.

本文引用的文献

1
Drugs that target dynamic microtubules: a new molecular perspective.靶向动态微管的药物:一种新的分子视角。
Med Res Rev. 2011 May;31(3):443-81. doi: 10.1002/med.20242. Epub 2011 Mar 4.
2
Mitosis is not a key target of microtubule agents in patient tumors.有丝分裂不是患者肿瘤中微管制剂的关键靶点。
Nat Rev Clin Oncol. 2011 Feb 1;8(4):244-50. doi: 10.1038/nrclinonc.2010.228.
3
Microwave-promoted selective mono-N-alkylation of anilines with tertiary amines by heterogeneous catalysis.微波促进下苯胺与叔胺的非均相催化选择性单-N-烷基化反应。
Chemistry. 2011 Jan 3;17(1):82-5. doi: 10.1002/chem.201002704. Epub 2010 Nov 24.
4
Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.水溶性微管靶向剂的合成与发现,该靶向剂与微管蛋白上的秋水仙素结合部位结合,并规避 Pgp 介导的耐药性。
J Med Chem. 2010 Nov 25;53(22):8116-28. doi: 10.1021/jm101010n. Epub 2010 Oct 25.
5
Microtubule-binding agents: a dynamic field of cancer therapeutics.微管结合剂:癌症治疗的一个充满活力的领域。
Nat Rev Drug Discov. 2010 Oct;9(10):790-803. doi: 10.1038/nrd3253.
6
Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4.2,5-二芳基-2,3-二氢-1,3,4-噁二唑啉类化合物的设计、合成及构效关系研究。
J Med Chem. 2010 Jan 14;53(1):325-34. doi: 10.1021/jm901268n.
7
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).血管破坏剂磷酸考布他汀A4(CA4P)的现状综述与更新
Expert Opin Investig Drugs. 2009 Feb;18(2):189-97. doi: 10.1517/13543780802691068.
8
The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.他卡缩醇内酯类:一类能规避临床上相关紫杉烷耐药机制的微管稳定剂。
Cancer Res. 2008 Nov 1;68(21):8881-8. doi: 10.1158/0008-5472.CAN-08-2037.
9
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.一项关于伐司朴达(PSC 833)联合紫杉醇和卡铂与单纯紫杉醇和卡铂相比,用于治疗IV期或初次减瘤不完全的III期上皮性卵巢癌或原发性腹膜癌患者的III期研究。
J Clin Oncol. 2008 Jun 1;26(16):2674-82. doi: 10.1200/JCO.2007.14.9807.
10
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?III类β-微管蛋白是接受微管蛋白结合剂治疗患者的预测因子吗?
Lancet Oncol. 2008 Feb;9(2):168-75. doi: 10.1016/S1470-2045(08)70029-9.